Change in urinary N-acetyl-β-d-glucosaminidase levels relevant to postprandial glycemic control conditions in subjects without diabetes mellitus

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 88-92

  Ouchi, Motoshi ^a   Oba, Kenzo ^a,b   Ohara, Makoto ^c   Igari, Yoshimasa ^a   Futami Suda, Shoko ^a   Ishii, Kazuhito ^a   Aoyama, Junya ^a   Onishi, Tetsuro ^a   Tsunoda Kubota, Misako ^a   Yamashita, Hidetoshi ^a   Suzuki, Tatsuya ^a   Nakano, Hiroshi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Department of Internal Medicine Oarai Coast Core Clinic   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,5 anhydroglucitol; Impaired glucose tolerance; N acetyl d glucosaminidase; Postprandial hyperglycemia; Renal tubular damage; Renal tubular injury

Indexed keywords

1,5 ANHYDROSORBITOL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; N ACETYL BETA GLUCOSAMINIDASE; 1,5-ANHYDROGLUCITOL; ACETYLGLUCOSAMINIDASE; BIOLOGICAL MARKER; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALCOHOL BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; BLOOD; METABOLISM; MIDDLE AGED; URINE; VERY ELDERLY; YOUNG ADULT;

ACETYLGLUCOSAMINIDASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CREATININE; DEOXYGLUCOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84896480375     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.035     Document Type: Article

References (53)

1. Tominaga M., Igarashi K., Eguchi H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
2. International Diabetes Federation Guideline for Management of Postmeal Glucose Available at, [Accessed October 7, 2013]. http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf.
3. Yamanouchi T., Tachibana Y., Akanuma H., et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992, 263(2 Pt 1):E268-E273.
4. Yamanouchi T., Akanuma H. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 1994, 24:S261-S268. [Suppl.].
5. Dungan K.M. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008, 8:9-19.
6. Yamanouchi T., Inoue T., Ogata E., et al. Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Lond) 2001, 101:227-233.
7. Rajabally Y.A. Neuropathy and impaired glucose tolerance: an updated review of the evidence. Acta Neurol Scand 2011, 124:1-8.
8. Klein R., Barrett-Connor E.L., Blunt B.A., Wingard D.L. Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed NIDDM. Diabetes Care 1991, 14:914-918.
9. Karadeniz S., Kir N., Yilmaz M.T., et al. Alteration of visual function in impaired glucose tolerance. Eur J Ophthalmol 1996, 6:59-62.
10. Gabir M.M., Hanson R.L., Dabelea D., et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000, 23:1113-1118.
11. Metcalf P.A., Baker J.R., Scragg R.K., Dryson E., Scott A.J., Wild C.J. Microalbuminuria in a middle-aged workforce: effect of hyperglycemia and ethnicity. Diabetes Care 1993, 16:1485-1493.
12. Pan X.R., Hu Y.H., Li G.W., Liu P.A., Bennett P.H., Howard B.V. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care 1993, 16:150-156.
13. Yuzawa Y., Ito I. Urinary NAG, β2 microglobulin - renal tubular injury, AKI (acute kidney injury) and biomarker. Nippon Naika Gakkai Zasshi 2008, 97:971-978. [Article in Japanese].
14. Vaidya V.S., Niewczas M.A., Ficociello L.H., et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-d-glucosaminidase. Kidney Int 2011, 79:464-470.
15. Whiting P.H., Nicholls A.J., Catto G.R.D., Edward N., Engeset J. Patterns of N-acetyl-β-d-glucosaminidase excretion after renal transplantation. Clin Chim Acta 1980, 108:1-7.
16. Diener U., Knoll E., Langer B., Rautenstrauch H., Ratge D., Wisser H. Urinary excretion of N-acetyl-β-d-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum. Clin Chim Acta 1981, 112:149-157.
17. Dance N., Price R.G., Cattell W.R., Lansdell J., Richards B. The excretion of N-acetyl-β-glucosaminidase and β-galactosidase by patients with renal disease. Clin Chim Acta 1970, 27:87-92.
18. Gibey R., Dupond J.L., Alber D. Leconte des Floris R, Henry JC. Predictive value of urinary N-acetyl-beta-d-glucosaminidase (NAG), alanine-aminopeptidase (AAP) and beta-2-microglobin (β2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta 1981, 116:25-34.
19. Fujita H., Narita T., Morii T., et al. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail 2002, 24:69-75.
20. Hiratsuka N., Shiba K., Nishida K., Iizima S., Kimura M., Kobayashi S. Analysis of urinary albumin, transferrin, N-acetyl-β-d-glucosaminidase and β2-microglobulin in patients with impaired glucose tolerance. J Clin Lab Anal 1998, 12:351-355.
21. Yamanouchi T., Kawasaki T., Yoshimura T., et al. Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care 1998, 21:619-624.
22. Ouchi M., Oba K., Motoyama M., et al. Postprandial glycemic control in relation to urinary N-acetyl-β-d-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. Diabetes Technol Ther 2013, [in press].
23. Ellis E.N., Brouhard B.H., Lagrone L., Travis L.B. Urinary excretion of N-acetyl-beta-d-glucosaminidase in children with type 1 diabetes mellitus. Diabetes Care 1983, 6:251-255.
24. L-Type NAG [package insert] 2013, Wako Pure Chemical Industries, Ltd., Osaka, Japan.
25. Stickle D., Turk J. A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 1997, 273:E821-E830.
26. Kim W.J., Park C.Y. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine 2013, 43:33-40.
27. Matsumoto K., Yano M., Miyake S., et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998, 21:256-260.
28. Yoshioka K., Azukari K., Yoshida T., Kondo M. Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor. Diabetes Care 1997, 20:462.
29. Buse J.B., Freeman J.L., Edelman S.V., Jovanovic L., McGill J.B. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003, 5:355-363.
30. Ouchi M., Oba K., Yamashita H., et al. Effects of sex and age on serum 1,5-anhydroglucitol in nondiabetic subjects. Exp Clin Endocrinol Diabetes 2012, 120:288-295.
31. Fukumura Y., Tajima S., Oshitani S., et al. Fully enzymatic method for detecting 1,5-anhydro-d-glucitol in serum. Clin Chem 1994, 40:2013-2016.
32. Yamanouchi T., Akanuma Y., Toyota T., et al. Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 1991, 40:52-57.
33. Watanabe M., Kokubo Y., Higashiyama A., Ono Y., Miyamoto Y., Okamura T. Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 2011, 216:477-483.
34. Watanabe K., Suzuki T., Ouchi M., et al. Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. BMC Cardiovasc Disord 2013, 13:11.
35. Kashiwagi A., Kasuga M., Araki E., et al. Committee on the standardization of diabetes mellitus-related laboratory testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012, 3:8-10.
36. Matsuo S., Imai E., Horio M., et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum Cr in Japan. Am J Kidney Dis 2009, 53:982-992.
37. Hsiao P.H., Tsai W.S., Tsai W.Y., Lee J.S., Tsau Y.K., Chen C.H. Urinary N-acetyl-beta-d-glucosaminidase activity in children with insulin-dependent diabetes mellitus. Am J Nephrol 1996, 16:300-303.
38. Nauta F.L., Boertien W.E., Bakker S.J., et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34:975-981.
39. Kim S.S., Song S.H., Kim I.J., et al. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract 2012, 97:251-257.
40. Fu W.J., Xiong S.L., Fang Y.G., et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012, 41:82-88.
41. Ouchi M., Suzuki T., Hashimoto M., et al. Urinary N-acetyl-β-d-glucosaminidase levels are positively correlated with 2-hour plasma glucose levels during oral glucose tolerance testing in prediabetes. J Clin Lab Anal 2012, 26:473-480.
42. Tazawa S., Yamato T., Fujikura H., et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci 2005, 76:1039-1050.
43. Yamanouchi T., Minoda S., Ogata N., et al. Prolonged hyperalimentation as a possible cause of renal tubular dysfunction: evaluation of 1,5-anhydro-d-glucitol resorption and N-acetylglucosaminidase excretion in humans. Clin Sci (Lond) 1995, 88:203-210.
44. Rabinowitch I.M. Glycosuria in pregnancy. Can Med Assoc J 1924, 14:375-376.
45. Hytten F.E. The renal excretion of nutrients in pregnancy. Postgrad Med J 1973, 49:625-629.
46. Tetsuo M., Hamada T., Yoshimatsu K., Ishimatsu J., Matsunaga T. Serum levels of 1,5-anhydro-d-glucitol during the normal and diabetic pregnancy and puerperium. Acta obstet Gynecol Scand 1990, 69:479-485.
47. Yoshida M., Furiya K., Takakuwa Y. Urinary excretion of N-acetyl-beta-d-glucosaminidase during normal pregnancy. Clin Chim Acta 1995, 235:113-115.
48. Fujisawa T., Ikegami H., Tsutsui T., et al. Renal tubular function affects glycosuria-related urinary excretion of 1,5-anhydroglucitol. Diabetes Care 1999, 22:863-864.
49. Kim W.J., Park C.Y., Lee K.B., et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care 2012, 35:281-286.
50. Oba K., Hirai M., Ajiro Y., et al. Effect of age on urinary excretion of N-acetyl-β-d-glucosaminidase. J Nippon Med Sch 1999, 66:33-36.
51. Magri C.J., Fava S. The role of tubular injury in diabetic nephropathy. Eur J Intern Med 2009, 20:551-555.
52. Phillips A., Janssen U., Floege J. Progression of diabetic nephropathy, Insights from cell culture studies and animal models. Kidney Blood Press Res 1999, 22:81-97.
53. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than aftermath of glomerular injury?. Kidney Int 1999, 56:1627-1637.